SCHEMBL259296

SCHEMBL259296

Cc1cccc(NC(=O)c2ccc(Cl)nc2)c1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.80
SMN1; SMN2 Q16637 6/20 0.80
MEN1 O00255 5/20 0.80
ALDH1A1 P00352 4/20 0.80
LMNA P02545 3/20 0.80
CYP1A2 P05177 1/20 0.70
CYP2D6 P10635 1/20 0.70
CYP2C9 P11712 1/20 0.70
CYP2C19 P33261 1/20 0.70
RAB9A P51151 4/20 0.70
RXFP1 Q9HBX9 1/20 0.61
KCNK3 O14649 3/20 0.59
POLB P06746 1/20 0.59
MAPT P10636 4/20 0.59
HTT P42858 2/20 0.59
NPSR1 Q6W5P4 1/20 0.59
GAA P10253 1/20 0.59
KCNQ3 O43525 1/20 0.58
KCNQ2 O43526 1/20 0.58
KCNK9 Q9NPC2 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4967489 0.89 KMT2A (0.63) KMT2ASMN1; SMN2MEN1ALDH1A1LMNA
SCHEMBL403487 0.84 SMN1; SMN2 (0.60) KMT2ASMN1; SMN2MEN1ALDH1A1LMNA
SCHEMBL259364 0.83 MEN1 (0.75) KMT2ASMN1; SMN2MEN1ALDH1A1LMNA
SCHEMBL2303956 0.83 KMT2A (0.66) KMT2ASMN1; SMN2MEN1ALDH1A1LMNA
SCHEMBL2306020 0.83 MEN1 (0.66) KMT2ASMN1; SMN2MEN1ALDH1A1LMNA
SCHEMBL2303815 0.83 KCNQ3 (0.77) KMT2ASMN1; SMN2MEN1ALDH1A1CYP1A2
SCHEMBL8361559 0.82 RAB9A (1.00) KMT2ASMN1; SMN2MEN1ALDH1A1LMNA
SCHEMBL23367927 0.82 KMT2A (0.69) KMT2ASMN1; SMN2MEN1ALDH1A1LMNA
SCHEMBL259362 0.82 MEN1 (0.73) KMT2ASMN1; SMN2MEN1ALDH1A1LMNA
SCHEMBL21620291 0.82 KMT2A (0.69) KMT2ASMN1; SMN2MEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
EP-1277738-B1 CONDENSED HETEROARYL DERIVATIVES ASTELLAS PHARMA INC (JP) 2011-03-30 EP disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A KMT2A 1722/4885SMN1; SMN2 4764/4885MEN1 3330/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A KMT2A 1722/4885SMN1; SMN2 4764/4885MEN1 3330/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A KMT2A 1722/4885SMN1; SMN2 4764/4885MEN1 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.